B. Metzler seel. Sohn & Co. AG Invests $1 Million in Vaxcyte, Inc. $PCVX

B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,235 shares of the company's stock, valued at approximately $1,002,000.

A number of other institutional investors have also recently made changes to their positions in PCVX. Smartleaf Asset Management LLC lifted its holdings in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock worth $27,000 after buying an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock worth $30,000 after acquiring an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock worth $34,000 after purchasing an additional 184 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company's stock valued at $49,000 after acquiring an additional 1,350 shares during the period. Finally, Capital Advisors Ltd. LLC bought a new position in shares of Vaxcyte in the first quarter worth approximately $58,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $62.62 on Monday. Vaxcyte, Inc. has a 52 week low of $29.87 and a 52 week high of $65.00. The stock has a market capitalization of $9.32 billion, a P/E ratio of -8.21 and a beta of 1.23. The firm has a fifty day simple moving average of $56.43 and a two-hundred day simple moving average of $55.79.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the business posted ($1.22) EPS. On average, analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the sale, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. This represents a 1.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $57.28, for a total value of $572,800.00. Following the completion of the sale, the chief financial officer owned 104,395 shares of the company's stock, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 120,646 shares of company stock valued at $6,570,810. Company insiders own 3.30% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PCVX. Zacks Research upgraded Vaxcyte from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Wall Street Zen raised Vaxcyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Vaxcyte in a report on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $86.00.

About Vaxcyte

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source